NCT06312189Enrolling by invitationPhase 3
Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada
Open-Label Study of Valbenazine for the Treatment of Chorea Associated With Huntington Disease in Canada
Source: ClinicalTrials.gov · Last updated 18 Jun 2026
Brief summary (registry, in English)
This study will evaluate long-term safety and tolerability of valbenazine in participants with chorea associated with Huntington Disease (HD) who participated in Study NBI-98854-HD3006 (NCT04400331) in Canada.
- Status (registry)
- Enrolling by invitation
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 7 (estimated)
- First submitted
- 8 Mar 2024
- Start date
- 24 Apr 2024
- Primary completion date
- Apr 2028
- Lead sponsor
- Neurocrine Biosciences
- Diseases
- Huntington's disease
- NCT number
- NCT06312189
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 7
- From 24 Apr 2024 to the primary completion date, Apr 2028
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Lab values
- Have a medically significant abnormality, physical examination finding, clinically significant laboratory abnormality
Other
- Have difficulty swallowing
- Are currently pregnant or breastfeeding
Who the study is looking for
- Participated in Study NBI-98854-HD3006 and completing dosing through the Week 156 visit; or were actively participating, receiving study treatment, and completed an early termination visit Study NBI-98854-HD3006 at the time of the study closure at sites in Canada.
- Participants of childbearing potential must agree to use contraception consistently while participating in the study until 30 days after last dose of the study treatment.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Ottawa | Canada | Unknown status |
| - Coordinator of this site? Confirm its status | Toronto | Canada | Unknown status |
| - Coordinator of this site? Confirm its status | Vancouver | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.